Thomas Klingebiel

Prof. Dr. Thomas Klingebiel

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKChristian Koelsche
Christian Koelsche
DSDaniel Schrimpf
Daniel Schrimpf
DSDamian Stichel
Damian Stichel
MSMartin Sill
Martin Sill
FSFelix Sahm
Felix Sahm
ADAndreas von Deimling
Andreas von Deimling
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. Therefore, the diagnosis of sarcomas is burdened with a high inter-observer variability and misclassification rate. Here, we demonstrate classification of soft tissue and bone tumours using a machine learning classifier algorithm based on array-generated DNA methylation data. This sarcoma classifier is trained using a dataset of 1077 methylation profiles from comprehensively pre-characterized cases comprising 62 tumour methylation classes constituting a broad range of soft tissue and bone sarcoma subtypes across the entire age spectrum. The performance is validated in a cohort of 428 sarcomatous tumours, of which 322 cases were classified by the sarcoma classifier. Our results demonstrate the potential of the DNA methylation-based sarcoma classification for research and future diagnostic applications.

11 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EKEwa Koscielniak
Ewa Koscielniak
BBBernd Blank
Bernd Blank
CVChristian Vokuhl
Christian Vokuhl
BKBernarda Kazanowska
Bernarda Kazanowska
RLRuth Ladenstein
Ruth Ladenstein
TKThomas Klingebiel
Thomas Klingebiel
We report here the results of the prospective, non-randomized, historically controlled CWS-2002P study in patients ≤ 21 years with localized RMS developed with the aim to improve the long-term outcome by adapting the burden of therapy to risk profile and to investigate the feasibility and relation to the outcome of maintenance therapy (MT) in the high-risk groups. Patients were allocated into low-risk (LR), standard-risk (SR), high-risk (HR), and very high-risk (VHR) groups. Chemotherapy consisted of vincristine (VCR) and dactinomycin (ACTO-D) for all patients with the addition of ifosfamide (IFO) in the SR, HR, and VHR and doxorubicin (DOX) in the HR and VHR groups. Low-dose cyclophosphamide and vinblastine maintenance therapy (MT) over 6 months was recommended in the HR and VHR groups. A total of 444 patients have been included in this analysis. With a median follow-up of 9·6 years (IQR 7·6–10·9) for patients alive, the 5-year EFS and OS for the whole group was 73% (95% CI 69–77) and 80% (95% CI 76–84), respectively. The 5-year EFS by risk group was 100% in the LR, 79% (95% CI 72–84) in the SR, 69% (95% CI 63–75) in the HR, and 42% (95% CI 23–61) in the VHR (log-rank p = 0.000). The 5-year EFS was 77% (95% CI 70–84) for 155 patients in the HR group who received MT as compared to 63% (95% CI 50–76) for 49 patients who did not (log-rank p = 0.015). Neither the reduction in the IFO dose in the SR nor the increased dose intensity of DOX in HR groups influenced the outcome when compared to the previous CWS and other European studies. MT was feasible, seemed to have an impact on prognosis, and should be studied in a well-controlled prospective trial in this patient population. The weighting of risk factors used for therapy stratification needs to be reevaluated.

19 September 2016 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AWA M Willasch
A M Willasch
ESE Salzmann-Manrique
E Salzmann-Manrique
TKT Krenn
T Krenn
MDM Duerken
M Duerken
JFJoerg Faber
Joerg Faber
Peter BaderPeter Bader
Peter Bader
Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant relapse. Eight patients received HDCHT/SIT, followed by haploidentical SCT in 7/8. Ten received LDCHT+DLI. The eight patients treated with a second transplant and the ten treated with the non-transplant approach had a 4-year overall survival of 56% and 40%, respectively (P=0.232). Prerequisites for successful treatment of post-transplant relapse by either a second transplant or experimental non-transplant approaches are good clinical condition and the capacity to achieve haematological remission by the induction treatment element.

30 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LTLars Tramsen
Lars Tramsen
KBKonrad Bochennek
Konrad Bochennek
MSMonika Sparber-Sauer
Monika Sparber-Sauer
ESEmilia Salzmann-Manrique
Emilia Salzmann-Manrique
MSMonika Scheer
Monika Scheer
TKThomas Klingebiel
Thomas Klingebiel
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma (STS) in childhood. Whereas more than 90% of patients with localized low-risk RMS can be cured, metastatic RMS have a dismal outcome, with survival rates of less than 30%. The HD CWS-96 trial showed an improved outcome for patients receiving maintenance therapy after completing intensive chemotherapy. Consequently, the international clinical trials CWS-IV 2002 and CWS DOK IV 2004 on metastatic disease of STS of the Cooperative Weichteilsarkom Studiengruppe (CWS) were designed in addition to the CWS-2002P trial for localized RMS disease. All patients received a multimodal intensive treatment regimen. To maintain remission, three options were compared: long-term maintenance therapy (LTMT) versus allogeneic hematopoietic stem cell transplantation (alloHSCT) versus high-dose chemotherapy (HDCT). A total of 176 pediatric patients with a histologically confirmed diagnosis of metastatic RMS or RMS-like tumor were included. A total of 89 patients receiving LTML showed a significantly better outcome, with an event-free survival (EFS) of 41% and an overall survival (OS) of 53%, than alloHSCT (n = 21, EFS 19%, p = 0.02, OS 24%, p = 0.002). The outcome of LTML was slightly improved compared to HDCT (n = 13, EFS 35%, OS 34%). In conclusion, our data suggest that in patients suffering from metastatic RMS, long-term maintenance therapy is a superior strategy in terms of EFS and OS compared to alloHSCT. EFS and OS of HDCT are similar in these strategies; however, the therapeutic burden of LTMT is much lower.

26 March 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SSSabine Stegmaier
Sabine Stegmaier
MSMonika Sparber-Sauer
Monika Sparber-Sauer
EAEsther Aakcha‐Rudel
Esther Aakcha‐Rudel
PMPetra Münch
Petra Münch
TRTheresa Reeh
Theresa Reeh
EKEwa Koscielniak
Ewa Koscielniak

8 December 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
FLFranco Locatelli
Franco Locatelli
GZGerhard Zugmaier
Gerhard Zugmaier
CRCarmelo Rizzari
Carmelo Rizzari
JMJoan D. Morris
Joan D. Morris
BGBernd Gruhn
Bernd Gruhn
ASArend von Stackelberg
Arend von Stackelberg